- Home
- About Us
- Message from the Chair of Pediatrics
- Our Facilities
- Faculty and Staff Resources
- Accomplishments Form
- Annual Reports
- Chair's Office Suggestion Box
- Contact Update Form
- Logos, Templates, and Brand Resources
- Meeting Archives
- Pitt Passport Integration
- Pitt Sponsored Account Request
- UPMC Personal Email and Cloud Storage Block
- Website Content Management
- Travel and Visitor Requests
- Frequently Asked Questions
- Divisions
- Adolescent and Young Adult Medicine
- Allergy and Immunology
- Blood and Marrow Transplantation and Cellular Therapies
- Cardiology
- Child Advocacy
- Emergency Medicine
- Endocrinology
- Gastroenterology, Hepatology and Nutrition
- General Academic Pediatrics
- Genetic and Genomic Medicine
- Health Informatics
- Hematology-Oncology
- Infectious Diseases
- Nephrology
- Neurology and Child Development Unit
- Newborn Medicine
- Paul C. Gaffney Division of Pediatric Hospital Medicine
- Pulmonology
- Rheumatology
- Centers & Institutes
- Center for Pediatric Research in Obesity and Metabolism
- Center for Rare Disease Therapy
- Children's Neuroscience Institute
- Cystic Fibrosis Research Center
- Institute for Infection, Inflammation, and Immunity in Children
- Pediatric Asthma Center
- Pediatric Institute for Heart Regeneration and Therapeutics
- Richard King Mellon Foundation Institute for Pediatric Research
- Pittsburgh Vaccine Trials Unit
- The Pittsburgh Study
- Research
- Research Administration
- Central Grants Management Office
- Pre-Award Administration
- Post-Award Administration
- Data Management and Reporting
- Rangos Research Center Building Administration
- Human Resources Administration
- Academic Finance
- Clinical Research Support Services
- Institutional Resources
- Frequently Requested Services
- Directory
- Cores and Research Support
- Information Technology
- Research Administration
- Diversity
- Education
- News
- People
Research
Clinical Research
The clinical research mission of the Division of Bone Marrow Transplant and Cellular Therapies is to design and test novel, disease-specific, and biologically rational reduced-toxicity transplantation regimens for life-threatening conditions. Transplant indications span from birth through adulthood and utilize human leukocyte antigen (HLA)-matched or mismatched bone marrow, cord blood, or autologous peripheral blood stem cell grafts.
- Neurodegenerative conditions/inborn errors of metabolism
- Primary Immune Deficiencies
- Autoimmune diseases/Immune dysregulation (Crohn’s Disease, Systemic Sclerosis)
- High risk acute leukemia
- RIC-MAC for AML/MDS
- Bone marrow failures and transfusion dependent anemias (Sickle cell disease, Thalassemia, Diamond-Blackfan Anemia)
Translational Research
Through our BOLT-BMT study, we are coordinating a first in human clinical trial that will explore the safety and efficacy of bone marrow transplant following solid organ transplant from the same cadaveric donor to establish immunity, tolerance, and extend organ survival. Our division is also researching tandem lung transplants and bone marrow transplants for primary immunodeficiency patients with end stage lung disease.
Our cellular immune therapy research aims to test regulatory T cell therapy for refractory autoimmune diseases and control life-threatening viral infections in immunocompromised children and adults.
Laboratory-Based Research
Our laboratory research projects aim to understand the development of immune competence alongside immune tolerance following HLA-mismatched bone marrow transplant and modulate metabolic pathways involved in graft-versus-host disease and anti-leukemia immunity.